Survanta 25 mg/mL

Survanta 25 mg/mL is a suspension used for respiratory support in premature infants. This single-use suspension, manufactured by AbbVie Inc., is administered endotracheally to aid lung function.

Survanta 25 mg/mL is primarily used to treat or prevent respiratory distress syndrome (RDS) in premature infants. This condition often occurs due to a lack of surfactant in the lungs, which is crucial for proper breathing. Survanta helps to improve lung function and reduce the need for oxygen therapy. It is administered endotracheally, directly into the airway, to provide immediate support.

Common effects of Survanta 25 mg/mL may include temporary changes in breathing patterns immediately following administration. Some infants may experience mild respiratory discomfort or require additional ventilation support. These effects are typically monitored and managed by healthcare professionals.

Survanta 25 mg/mL should be handled with care, ensuring proper storage and administration techniques. It is a single-use suspension, and any unused portion should be discarded. Healthcare providers should follow strict hygiene protocols to prevent contamination. Always consult a healthcare professional for specific handling instructions.

Survanta 25 mg/mL may interact with other medications administered endotracheally. It is important to inform healthcare providers about all medications the infant is receiving. Additionally, certain medical conditions may affect the use of Survant. Always consult a healthcare professional for personalized advice.